Triple Combination Therapy for Richter’s Transformation - Dr. Tamar Tadmor ASH 2023

Why should CD19 CAR-T be the preferred therapy for Richter's transformation?Подробнее

Investigating the safety and efficacy of re-treating CLL patients with venetoclax-based regimensПодробнее

Novel treatment regimens under investigation for Richter's transformationПодробнее

Pirtobrutinib for Richter's Transformation - Dr. William Wierda ASH 2023Подробнее

CAR-T Therapy for Richter Transformation - Dr. Adam Kittai ASH 2023Подробнее

CLL highlights from ASH: the Phase III AMPLIFY trialПодробнее

Richter's Transformation & CAR T Therapy in #CLL | Dr. Adam Kittai, MD | ASH 2023Подробнее

A research update in Richter's transformation from ASH 2023Подробнее

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformationПодробнее

Phase I trial of copanlisib + nivolumab in patients with Richter’s transformation or transformed FLПодробнее

The use of anti-CD19 CAR-T therapy for Richter’s transformationПодробнее

Var-cel shows promise for the treatment of CLL and Richter's transformationПодробнее

Latest advances in CAR-T therapy for CLL and Richter’s transformationПодробнее

A study investigating the efficacy of CAR-T therapy in Richter's transformationПодробнее

Novel approaches in Richter's transformation: CAR-T and bispecificsПодробнее

The current SoC in Richter’s transformation and the potential role of CAR T-cell therapyПодробнее

Promising agents emerging for Richter’s transformationПодробнее

In-vivo modeling of CLL and Richter's transformationПодробнее